DK2621481T3 - Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser - Google Patents

Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser Download PDF

Info

Publication number: DK2621481T3
Authority: DK; Denmark
Prior art keywords: castration; vegf; met; treatment; prostate cancer
Prior art date: 2010-09-27

Application number

DK11764655.4T

Other languages

English (en)

Other versions

DK2621481T4 (da

Inventor

David Smith

Maha Hussain

Original Assignee

Exelixis Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-09-27

Filing date

2011-09-26

Publication date

2019-10-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44741730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2621481(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-09-26 Application filed by Exelixis Inc filed Critical Exelixis Inc

2019-10-21 Application granted granted Critical

2019-10-21 Publication of DK2621481T3 publication Critical patent/DK2621481T3/da

2023-01-09 Publication of DK2621481T4 publication Critical patent/DK2621481T4/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Quinoline Compounds (AREA)
Steroid Compounds (AREA)
Peptides Or Proteins (AREA)

DK11764655.4T 2010-09-27 2011-09-26 Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser DK2621481T4 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US38695910P	2010-09-27	2010-09-27
US201161481671P	2011-05-02	2011-05-02
PCT/US2011/053233 WO2012044572A1 (en)	2010-09-27	2011-09-26	Dual inhibitors of met and vegf for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases

Publications (2)

Publication Number	Publication Date
DK2621481T3 true DK2621481T3 (da)	2019-10-21
DK2621481T4 DK2621481T4 (da)	2023-01-09

Family

ID=44741730

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK11764655.4T DK2621481T4 (da)	2010-09-27	2011-09-26	Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser

Country Status (22)

Country	Link
US (5)	US20140057943A1 (da)
EP (1)	EP2621481B2 (da)
JP (2)	JP6158705B2 (da)
KR (1)	KR101882328B1 (da)
CN (1)	CN103402505A (da)
AR (1)	AR085195A1 (da)
AU (2)	AU2011307304C1 (da)
BR (1)	BR112013007220A2 (da)
CA (1)	CA2812750C (da)
DK (1)	DK2621481T4 (da)
EA (1)	EA027476B1 (da)
ES (1)	ES2754973T5 (da)
FI (1)	FI2621481T4 (da)
HU (1)	HUE045810T2 (da)
IL (1)	IL225507B (da)
MX (1)	MX352926B (da)
PL (1)	PL2621481T5 (da)
PT (1)	PT2621481T (da)
SI (1)	SI2621481T2 (da)
TW (2)	TW201302709A (da)
UA (1)	UA114172C2 (da)
WO (1)	WO2012044572A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2387563B2 (en)	2009-01-16	2022-04-27	Exelixis, Inc.	Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quinolin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
WO2012009722A1 (en)	2010-07-16	2012-01-19	Exelixis, Inc.	C-met modulator pharmaceutical compositions
FI2621481T4 (fi)	2010-09-27	2023-01-13		Met- ja vegf-kaksoisestäjiä kastraatioresistentin eturauhassyövän ja osteoblastisten luun etäispesäkkeiden hoitamiseen
EP4019498A1 (en)	2011-02-10	2022-06-29	Exelixis, Inc.	Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
US20120252840A1 (en)	2011-04-04	2012-10-04	Exelixis, Inc.	Method of Treating Cancer
US20140179736A1 (en) *	2011-05-02	2014-06-26	Exelixis, Inc.	Method of Treating Cancer and Bone Cancer Pain
MX351133B (es) *	2011-09-22	2017-10-03	Exelixis Inc	Metodo para tratar osteoporosis.
AR088483A1 (es)	2011-10-20	2014-06-11	Exelixis Inc	Proceso para preparar derivados de quinolina
JP2014532766A (ja) *	2011-11-08	2014-12-08	エクセリクシス，インク．	癌を治療する、ｍｅｔ及びｖｅｇｆの二重阻害剤
EP2844254A1 (en)	2012-05-02	2015-03-11	Exelixis, Inc.	A dual met - vegf modulator for treating osteolytic bone metastases
CN103664776B (zh) *	2012-09-26	2016-05-04	正大天晴药业集团股份有限公司	一种酪氨酸激酶抑制剂及其中间体的制备方法
MX366003B (es)	2013-03-15	2019-06-24	Exelixis Inc	Metabolitos de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n' -(4-fluorofenil)ciclopropan-1,1-dicarboxamida.
WO2014165779A1 (en) *	2013-04-04	2014-10-09	Exelixis, Inc.	Drug combinations to treat cancer
ES2927651T3 (es)	2013-04-04	2022-11-10	Exelixis Inc	Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
EP3738952A1 (en)	2014-02-14	2020-11-18	Exelixis, Inc.	Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
JP6666849B2 (ja)	2014-03-17	2020-03-18	エグゼリクシス，インコーポレイテッド	カボザンチニブ製剤の投与
CN104788372B (zh) *	2014-07-25	2018-01-30	上海圣考医药科技有限公司	一种氘代卡博替尼衍生物、其制备方法、应用及其中间体
EA033834B1 (ru)	2014-07-31	2019-11-29	Exelixis Inc	Способ получения кабозантиниба, меченного фтором-18, и его аналогов
MA40457A (fr)	2014-08-05	2017-06-14	Exelixis Inc	Combinaison de médicaments pour traiter le myélome multiple
EP3219205A1 (en) *	2016-03-18	2017-09-20	Nihon Medi-Physics Co., Ltd.	Method for producing a non human animal model of osteoblastic bone metastasis
US11141413B2 (en)	2016-04-15	2021-10-12	Exelixis, Inc.	Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
CN108503650B (zh) *	2017-02-27	2021-02-12	北京赛特明强医药科技有限公司	二噁烷并喹唑啉类化合物或其药用盐或其水合物及其作为酪氨酸激酶抑制剂的应用
WO2019154133A1 (zh) *	2018-02-11	2019-08-15	北京赛特明强医药科技有限公司	二噁烷并喹啉类化合物及其制备方法与应用
WO2018218233A1 (en)	2017-05-26	2018-11-29	Exelixis, Inc.	Crystalline solid forms of salts of n-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-n'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
WO2019133632A1 (en)	2017-12-27	2019-07-04	St. Jude Children's Research Hospital	Methods of treating disorders associated with castor
IL275658B2 (en)	2017-12-27	2024-04-01	St Jude Childrens Res Hospital Inc	Small molecule modulators of pantothenate kinases
EP4647127A3 (en)	2018-01-26	2025-12-17	Exelixis, Inc.	Compounds for the treatment of kinase-dependent disorders
CN115569137A (zh)	2018-06-15	2023-01-06	汉达癌症医药责任有限公司	激酶抑制剂的盐类及其组合物
WO2022133034A1 (en) *	2020-12-16	2022-06-23	St. Jude Children's Research Hospital, Inc.	Methods of treating disorders associated with castor
AU2024215796A1 (en)	2023-01-31	2025-05-15	Handa Oncology, Llc	Improved cabozantinib compositions and methods of use

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4107288A (en)	1974-09-18	1978-08-15	Pharmaceutical Society Of Victoria	Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en)	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
WO2003033472A1 (en)	2001-10-17	2003-04-24	Kirin Beer Kabushiki Kaisha	Quinoline or quinazoline derivatives inhibiting auto- phosphorylation of fibroblast growth factor receptors
GB0219746D0 (en)	2002-08-23	2002-10-02	Inst Of Ex Botany Ascr	Azapurine derivatives
JP3763414B2 (ja)	2002-10-21	2006-04-05	麒麟麦酒株式会社	Ｎ−｛２−クロロ−４−［（６，７−ジメトキシ−４−キノリル）オキシ］フェニル｝−ｎ’−（５−メチル−３−イソキサゾリル）ウレアの塩の結晶形
AU2003280599A1 (en)	2002-10-29	2004-05-25	Kirin Beer Kabushiki Kaisha	QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
DK1562955T3 (da)	2002-11-04	2008-06-02	Astrazeneca Ab	Quinazolinderivater som Src-tyrosinkinaseinhibitorer
US20040156869A1 (en)	2002-12-13	2004-08-12	Neurogen Corporation	2-substituted quinazolin-4-ylamine analogues
PL377686A1 (pl)	2002-12-18	2006-02-06	Pfizer Products Inc.	Pochodne 4-anilinochinazoliny do leczenia anormalnego wzrostu komórek
AU2003299943A1 (en)	2002-12-23	2004-07-22	Ariad Pharmaceuticals, Inc.	Heterocycles and uses thereof
WO2004060373A1 (ja)	2002-12-27	2004-07-22	Santen Pharmaceutical Co., Ltd.	滲出型加齢黄斑変性治療剤
ES2436888T3 (es)	2003-09-26	2014-01-07	Exelixis, Inc	Moduladores c-Met y métodos de uso
US7977345B2 (en)	2004-07-02	2011-07-12	Exelixis, Inc.	c-MET modulators and method of use
WO2006108059A1 (en)	2005-04-06	2006-10-12	Exelixis, Inc.	C-met modulators and methods of use
US20080004273A1 (en)	2006-05-30	2008-01-03	Stephane Raeppel	Inhibitors of protein tyrosine kinase activity
PL2101759T3 (pl)	2006-12-14	2019-05-31	Exelixis Inc	Sposoby stosowania inhibitorów MEK
US20080200515A1 (en)	2006-12-29	2008-08-21	Tap Pharmaceutical Products Inc.	Solid state forms of enantiopure ilaprazole
KR101556269B1 (ko) *	2007-08-29	2015-09-30	메틸진 인코포레이티드	단백질 티로신 키나아제 활성의 억제제
TW200922590A (en) *	2007-09-10	2009-06-01	Curis Inc	VEGFR inhibitors containing a zinc binding moiety
UY31800A (es)	2008-05-05	2009-11-10	Smithkline Beckman Corp	Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
EP2288383A1 (en) *	2008-05-14	2011-03-02	Amgen, Inc	Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
UY32142A (es)	2008-09-26	2010-05-31	Smithkline Beckman Corp	Preparación de una quinoliniloxidifenilciclopropanodicarboxamida
AU2009300328A1 (en)	2008-10-01	2010-04-08	Ludwig Institute For Cancer Research	Methods for the treatment of cancer
NZ592827A (en)	2008-11-13	2013-06-28	Exelixis Inc	Methods of preparing quinoline derivatives
JP2010126530A (ja) *	2008-12-01	2010-06-10	Takeda Chem Ind Ltd	縮合複素環誘導体およびその用途
WO2010065838A1 (en)	2008-12-04	2010-06-10	Exelixis, Inc.	Methods of preparing quinoline derivatives
EP2387563B2 (en)	2009-01-16	2022-04-27	Exelixis, Inc.	Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quinolin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
EP2454238A1 (en)	2009-07-17	2012-05-23	Exelixis, Inc.	Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2475390A4 (en)	2009-09-09	2014-01-01	Quintiles Transnat Corp	METHODS AND COMPOSITIONS FOR THE TREATMENT OF TYROSINE KINASE RECEPTOR MEDIATION DISEASES OR DISORDERS
TW201202228A (en)	2010-03-12	2012-01-16	Exelixis Inc	Hydrated crystalline forms of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
US20120070368A1 (en)	2010-04-16	2012-03-22	Exelixis, Inc.	Methods of Using C-Met Modulators
WO2012009722A1 (en)	2010-07-16	2012-01-19	Exelixis, Inc.	C-met modulator pharmaceutical compositions
US20140186407A9 (en)	2010-07-16	2014-07-03	Exelixis Inc.	C-Met Modulator Pharmaceutical Compositions
AU2011307306A1 (en)	2010-09-27	2013-05-02	Exelixis, Inc.	Dual inhibitors of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
EP2621483A1 (en)	2010-09-27	2013-08-07	Exelixis, Inc.	Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
FI2621481T4 (fi)	2010-09-27	2023-01-13		Met- ja vegf-kaksoisestäjiä kastraatioresistentin eturauhassyövän ja osteoblastisten luun etäispesäkkeiden hoitamiseen
EP2643001A4 (en)	2010-11-22	2014-02-19	Glaxosmithkline Ip Dev Ltd	METHOD OF TREATING CANCER
EP4019498A1 (en)	2011-02-10	2022-06-29	Exelixis, Inc.	Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
US20120252840A1 (en)	2011-04-04	2012-10-04	Exelixis, Inc.	Method of Treating Cancer
US20140179736A1 (en)	2011-05-02	2014-06-26	Exelixis, Inc.	Method of Treating Cancer and Bone Cancer Pain
TW201306842A (zh)	2011-06-15	2013-02-16	Exelixis Inc	使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
MX351133B (es)	2011-09-22	2017-10-03	Exelixis Inc	Metodo para tratar osteoporosis.
AR088483A1 (es)	2011-10-20	2014-06-11	Exelixis Inc	Proceso para preparar derivados de quinolina
JP2014532766A (ja)	2011-11-08	2014-12-08	エクセリクシス，インク．	癌を治療する、ｍｅｔ及びｖｅｇｆの二重阻害剤
EP2844254A1 (en)	2012-05-02	2015-03-11	Exelixis, Inc.	A dual met - vegf modulator for treating osteolytic bone metastases
CN104703600A (zh)	2012-09-07	2015-06-10	埃克塞里艾克西斯公司	用于治疗肺腺癌的met、vegfr和ret的抑制剂
US20140221372A1 (en)	2013-02-06	2014-08-07	GlaxoSmithKline Intellectual Property (NO 2.) Limited	Method of administration and treatment
MX366003B (es)	2013-03-15	2019-06-24	Exelixis Inc	Metabolitos de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n' -(4-fluorofenil)ciclopropan-1,1-dicarboxamida.
WO2014165779A1 (en)	2013-04-04	2014-10-09	Exelixis, Inc.	Drug combinations to treat cancer

2011
- 2011-09-26 FI FIEP11764655.4T patent/FI2621481T4/fi active
- 2011-09-26 AU AU2011307304A patent/AU2011307304C1/en active Active
- 2011-09-26 JP JP2013530386A patent/JP6158705B2/ja active Active
- 2011-09-26 SI SI201131802T patent/SI2621481T2/sl unknown
- 2011-09-26 PT PT117646554T patent/PT2621481T/pt unknown
- 2011-09-26 WO PCT/US2011/053233 patent/WO2012044572A1/en not_active Ceased
- 2011-09-26 PL PL11764655.4T patent/PL2621481T5/pl unknown
- 2011-09-26 US US13/876,290 patent/US20140057943A1/en not_active Abandoned
- 2011-09-26 CN CN2011800565800A patent/CN103402505A/zh active Pending
- 2011-09-26 EP EP11764655.4A patent/EP2621481B2/en active Active
- 2011-09-26 ES ES11764655T patent/ES2754973T5/es active Active
- 2011-09-26 UA UAA201305315A patent/UA114172C2/uk unknown
- 2011-09-26 CA CA2812750A patent/CA2812750C/en active Active
- 2011-09-26 EA EA201390465A patent/EA027476B1/ru not_active IP Right Cessation
- 2011-09-26 KR KR1020137010372A patent/KR101882328B1/ko active Active
- 2011-09-26 MX MX2013003594A patent/MX352926B/es active IP Right Grant
- 2011-09-26 HU HUE11764655A patent/HUE045810T2/hu unknown
- 2011-09-26 DK DK11764655.4T patent/DK2621481T4/da active
- 2011-09-27 AR ARP110103539A patent/AR085195A1/es unknown
- 2011-09-27 TW TW100134883A patent/TW201302709A/zh unknown
- 2011-09-27 TW TW106105784A patent/TW201738213A/zh unknown
- 2011-11-26 BR BR112013007220A patent/BR112013007220A2/pt not_active IP Right Cessation
2013
- 2013-04-02 IL IL225507A patent/IL225507B/en active IP Right Grant
2015
- 2015-09-02 US US14/843,480 patent/US20160220554A1/en not_active Abandoned
2016
- 2016-07-08 AU AU2016204747A patent/AU2016204747A1/en not_active Abandoned
2017
- 2017-02-28 JP JP2017036322A patent/JP2017149714A/ja active Pending
2020
- 2020-06-18 US US16/905,307 patent/US11612597B2/en active Active
2023
- 2023-02-21 US US18/112,214 patent/US11969419B2/en active Active
2024
- 2024-01-26 US US18/423,824 patent/US20240156803A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20200330450A1 (en)	2020-10-22
US11969419B2 (en)	2024-04-30
TW201302709A (zh)	2013-01-16
AR085195A1 (es)	2013-09-18
IL225507A0 (en)	2013-06-27
TW201738213A (zh)	2017-11-01
IL225507B (en)	2019-08-29
PT2621481T (pt)	2019-11-19
HUE045810T2 (hu)	2020-01-28
EP2621481B1 (en)	2019-08-14
MX2013003594A (es)	2013-08-01
BR112013007220A2 (pt)	2017-08-08
EA027476B1 (ru)	2017-07-31
PL2621481T5 (pl)	2023-03-13
FI2621481T4 (fi)	2023-01-13
US20140057943A1 (en)	2014-02-27
ES2754973T5 (es)	2023-03-13
JP2017149714A (ja)	2017-08-31
UA114172C2 (uk)	2017-05-10
US20230301980A1 (en)	2023-09-28
KR20140025304A (ko)	2014-03-04
PL2621481T3 (pl)	2020-03-31
MX352926B (es)	2017-12-14
CA2812750A1 (en)	2012-04-05
US11612597B2 (en)	2023-03-28
SI2621481T1 (sl)	2019-11-29
CN103402505A (zh)	2013-11-20
ES2754973T3 (es)	2020-04-21
AU2011307304C1 (en)	2016-10-20
JP2013537916A (ja)	2013-10-07
SI2621481T2 (sl)	2023-02-28
US20160220554A1 (en)	2016-08-04
DK2621481T4 (da)	2023-01-09
WO2012044572A1 (en)	2012-04-05
CA2812750C (en)	2020-10-06
US20240156803A1 (en)	2024-05-16
EP2621481B2 (en)	2022-10-19
KR101882328B1 (ko)	2018-07-27
JP6158705B2 (ja)	2017-07-05
EA201390465A1 (ru)	2013-08-30
EP2621481A1 (en)	2013-08-07
AU2011307304B2 (en)	2016-04-14
AU2011307304A1 (en)	2013-05-02
AU2016204747A1 (en)	2016-07-28

Publication	Publication Date	Title
DK2621481T4 (da)	2023-01-09	Dobbelte inhibitorer af MET og VEGF til behandling af kastrationsresistent prostatacancer og osteoblastiske knoglemetastaser
DK3825692T3 (da)	2024-10-28	Fremgangsmåde til prognose og behandling af kræftmetastaser
IL224370B (en)	2018-04-30	Combination treatment for prostate carcinoma
DK2507211T3 (da)	2014-09-29	Apoptosefremkaldende midler til behandling af cancer og immun- og autoimmun-sygdomme
DK3838923T3 (da)	2024-07-29	Antistoffer og vacciner til anvendelse ved behandling af ror1-cancere og hæmning af metastase
DK3178849T3 (da)	2019-07-01	Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer
DK2785744T3 (da)	2017-11-27	Proteininhibitorer til komplement- og vegf-pathways og fremgangsmåder til anvendelse deraf
DK2632954T4 (da)	2021-08-09	Midler og fremgangsmåder til behandling af dlbcl
PL2552438T3 (pl)	2016-12-30	Sposoby leczenia raka wątrobowokomórkowego
DK3444342T3 (da)	2020-08-24	Fremgangsmåder og sammensætninger til behandlingen af lysosomale aflejringssygdomme
DK2340042T3 (da)	2014-10-27	Fremgangsmåder og præparater til behandling af cancer
DK2558105T3 (da)	2020-01-27	Bardoxolonmethyl til behandling af fedme
DK2790738T3 (da)	2019-08-26	Biomarkører for kollateral geninaktivering og mål for cancerterapi
DK3443957T3 (da)	2020-12-21	Forbindelser og sammensætninger til behandling af cancer
DK2473510T3 (da)	2014-10-20	Jak-2-hæmmere og anvendelse heraf til behandling af myeloproliferativesygdomme og cancer
DK2532366T3 (da)	2017-01-02	Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
IL223201A (en)	2015-05-31	Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
DK3400944T3 (da)	2020-10-12	Ibat-inhibitorer til behandling af leversygdomme
EA201490944A1 (ru)	2014-10-30	Двойной ингибитор met и vegf для лечения рака
DK3246042T3 (da)	2019-10-14	Lægemiddelresistent immunterapi til behandling af cancer
DK2544679T3 (da)	2019-07-22	Pde10-inhibitorer og relaterede sammensætninger og fremgangsmåder
DK2398902T3 (da)	2023-12-04	Fremgangsmåder og sammensætninger til diagnosticering og behandling af cancer
IL225262A0 (en)	2013-06-27	Methods and compositions for treating lung cancer
ITTO20110641A1 (it)	2012-01-16	Composizioni farmaceutiche e metodi di trattamento
EA202190820A1 (ru)	2021-10-29	Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты